CurrentCignaPolicy IP0297

Erythropoiesis-Stimulating Agents — Mircera (methoxy polyethylene glycol-epoetin beta)

Defines Cigna prior authorization, coverage criteria, dosing limits, and excluded uses for Mircera for anemia due to chronic kidney disease (CKD) in adults and pediatric patients converting from other ESAs; applies to Cigna-administered health benefit plans and provider billing for the drug.

Policy Summary

PayerCigna

PolicyErythropoiesis-Stimulating Agents — Mircera

Policy CodePolicy IP0297

Change TypeCriteria and dosing revisionspediatric conversion clarification

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document patient age, hemoglobin values, iron status or therapy, prior ESA use and Hb stabilization for pediatric conversions.

SourceLink

POLICY UPDATE CHANGES

Removed age requirement for 'Patient Currently Receiving an Erythropoiesis-Stimulating Agent' criterion; previously required ≥ 18 years.

Added requirement that Hb level has been stabilized by treatment with an ESA for patients < 18 years.

Dosing: Added a requirement that the patient be ≥ 18 years for the every-2-weeks dosing regimen (≤180 mcg every ≥2 weeks).

3 yrsCKD on dialysis

1 yrCKD not on dialysis

Hb <10 g/dLESA initiation threshold

180 mcg q2w or 360 mcg qm

Policy Summary

PayerCigna

PolicyErythropoiesis-Stimulating Agents — Mircera

Policy CodePolicy IP0297

Change TypeCriteria and dosing revisionspediatric conversion clarification

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document patient age, hemoglobin values, iron status or therapy, prior ESA use and Hb stabilization for pediatric conversions.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Initial and Ongoing Therapy Criteria

Mircera is medically necessary when ONE of the following is met:

FDA Indications

1. CKD on Dialysis: Anemia in a patient with chronic kidney disease who is on dialysis
Approve for 3 years
2. CKD not on Dialysis - Initial Therapy: Patient is ≥ 18 years of age; AND patient has a hemoglobin < 10.0 g/dL; AND patient meets ONE of the following: patient is currently receiving iron therapy OR patient has adequate iron stores according to the prescriber
Approve for 1 year
2. CKD not on Dialysis - Currently Receiving an ESA: If patient < 18 years, prescriber states hemoglobin level has been stabilized by treatment with an erythropoiesis-stimulating agent; AND patient has a hemoglobin ≤ 12.0 g/dL; AND patient meets ONE of the following: patient is currently receiving iron therapy OR patient has adequate iron stores according to the prescriber
Approve for 1 year

1. CKD on Dialysis: Anemia in a patient with chronic kidney disease who is on dialysis

Approve for 3 years

2. CKD not on Dialysis - Initial Therapy: Patient is ≥ 18 years of age; AND patient has a hemoglobin < 10.0 g/dL; AND patient meets ONE of the following: patient is currently receiving iron therapy OR patient has adequate iron stores according to the prescriber

Approve for 1 year

2. CKD not on Dialysis - Currently Receiving an ESA: If patient < 18 years, prescriber states hemoglobin level has been stabilized by treatment with an erythropoiesis-stimulating agent; AND patient has a hemoglobin ≤ 12.0 g/dL; AND patient meets ONE of the following: patient is currently receiving iron therapy OR patient has adequate iron stores according to the prescriber

Approve for 1 year

Dosing Criteria

Approve if dosing meets ONE of the following regimens:

Dosing Regimens

Regimen A (q2w): Patient is ≥ 18 years of age; AND each dose is ≤ 180 mcg; AND each dose given no more frequently than once every 2 weeks
Regimen B (monthly): Each dose is ≤ 360 mcg; AND each dose given no more frequently than once monthly

Regimen A (q2w): Patient is ≥ 18 years of age; AND each dose is ≤ 180 mcg; AND each dose given no more frequently than once every 2 weeks

Regimen B (monthly): Each dose is ≤ 360 mcg; AND each dose given no more frequently than once monthly

The following uses of Mircera are considered not medically necessary and are excluded from coverage: anemia associated with cancer in patients receiving myelosuppressive chemotherapy; use to enhance athletic performance; and treatment of anemia due to acute blood loss. This list is not all-inclusive and may be updated as new published data become available.

Mircera for any other use not specifically listed as medically necessary in this policy is considered not medically necessary. Examples include chemotherapy-associated anemia, enhancement of athletic performance, and anemia from acute blood loss.

Coding, Hemoglobin Thresholds, and Dose Limits

Considered Medically Necessary when criteria metHCPCSCovered

J0887	Injection, epoetin beta, 1 mcg, (for ESRD on dialysis).
J0888	Injection, epoetin beta, 1 mcg, (for non-ESRD use).

inv-06: Hemoglobin thresholds — initiation thresholds for adults and notes on pediatric thresholds

Adult initiation thresholdInitiate ESA therapy for adults with CKD on dialysis when hemoglobin (Hb) < 10.0 g/dL; for adults with CKD not on dialysis consider initiation when Hb < 10.0 g/dL

Adult Hb upper cautionIf Hb approaches or exceeds 11.0 g/dL in adults, reduce or interrupt Mircera; use the lowest effective dose to avoid transfusions

Pediatric initiation requirementPediatric patients (3 months to 17 years) should only be initiated on Mircera when Hb has been stabilized by prior treatment with another ESA (conversion therapy)

Pediatric Hb upper cautionIf pediatric Hb approaches or exceeds 12.0 g/dL, reduce or interrupt the Mircera dose

inv-07: Dosing limits — Option A and Option B maximums and age restrictions

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required for benefit coverage of Mircera in patients with conditions other than CKD who are on dialysis. Typical approval durations: Approve for 3 years for anemia in CKD patients on dialysis; approve for 1 year for anemia in CKD patients not on dialysis when initial or continuation criteria are met. All approvals are provided for the duration noted in the policy.

PA required for Mircera for indications other than CKD with dialysis.
Approval durations: 3 years (CKD on dialysis); 1 year (CKD not on dialysis when criteria met).

Step Therapy

Conversion / Step Requirement for Patients Previously on an ESA

Conversion/step requirement: For pediatric patients (<18 years) who are currently receiving an erythropoiesis-stimulating agent (ESA) and for whom Mircera is requested, the prescriber must document that the hemoglobin level has been stabilized by treatment with an ESA. For adults and pediatrics switching from another ESA, the request must meet the policy Hemoglobin thresholds and iron status requirements described in the FDA-Approved Indications (e.g., hemoglobin ≤ 12.0 g/dL for patients currently receiving an ESA).

Key Definitions and Assessment Requirements

inv-13: Conversion therapy (pediatrics) — pediatric initiation only after Hb stabilized on another ESA

Conversion requirement (pediatrics)Pediatric patients (< 18 years) converting to Mircera must have hemoglobin stabilized by prior treatment with another ESA before initiating Mircera

Eligible pediatric age rangePolicy indicates pediatric patients 3 months to 17 years may convert to Mircera after Hb stabilization with an ESA

Documentation expectedPrescriber must attest that Hb was stabilized on an ESA to meet conversion pathway criteria

inv-14: Iron assessment — evaluation and correction of iron deficiency before and during ESA therapy

Pre-treatment iron assessmentEvaluate iron status (e.g., transferrin saturation, ferritin) in all patients before initiating ESA therapy

Correct iron deficiency

Background

Mircera is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults (on dialysis and not on dialysis) and in pediatric patients aged 3 months to 17 years who are converting from another ESA after their hemoglobin (Hb) level has been stabilized. Iron status should be evaluated before and during therapy. Initiation guidance includes starting therapy in adults with CKD on dialysis when Hb is < 10.0 g/dL; if Hb approaches or exceeds 11.0 g/dL in adults, reduce or interrupt Mircera. For pediatric conversion recipients, Mircera should only be initiated after Hb stabilization on another ESA, and if Hb approaches or exceeds 12.0 g/dL, reduce or interrupt dosing.